|
1
|
Fedewa SA, Ma J, Sauer AG, Siegel RL,
Smith RA, Wender RC, Doroshenk MK, Brawley OW, Ward EM and Jemal A:
How many individuals will need to be screened to increase
colorectal cancer screening prevalence to 80% by 2018? Cancer.
121:4258–4265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng ZX, Zheng RS, Zhang SW and Chen WQ:
Colorectal cancer incidence and mortality in China, 2010. Asian Pac
J Cancer Prev. 15:8455–8460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gellad ZF and Provenzale D: Colorectal
cancer: National and international perspective on the burden of
disease and public health impact. Gastroenterology. 138:2177–2190.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen S, Chen X, Xiu YL, Sun KX and Zhao Y:
MicroRNA-490 3P targets CDK1 and inhibits ovarian epithelial
carcinoma tumorigenesis and progression. Cancer Lett. 362:122–130.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Šulc M, Marín RM, Robins HS and Vaníček J:
PACCMIT/PACCMIT-CDS: Identifying microRNA targets in 3′ UTRs and
coding sequences. Nucleic Acids Res. 43:W474–9. 2015. View Article : Google Scholar
|
|
6
|
Fang Z, Tang J, Bai Y, Lin H, You H, Jin
H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24,
microRNA-320a, and microRNA-423 5p are potential biomarkers for
colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar
|
|
7
|
Nishikawa R, Goto Y, Kurozumi A,
Matsushita R, Enokida H, Kojima S, Naya Y, Nakagawa M, Ichikawa T
and Seki N: MicroRNA-205 inhibits cancer cell migration and
invasion via modulation of centromere protein F regulating pathways
in prostate cancer. Int J Urol. 22:867–877. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen W, Fan XM, Mao L, Zhang JY, Li J, Wu
JZ and Tang JH: MicroRNA-224: As a potential target for miR-based
therapy of cancer. Tumour Biol. 36:6645–6652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tyagi N, Arora S, Deshmukh SK, Singh S,
Marimuthu S and Singh AP: Exploiting nanotechnology for the
development of microRNA-based cancer therapeutics. J Biomed
Nanotechnol. 12:28–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barger JF and Nana-Sinkam SP: MicroRNA as
tools and therapeutics in lung cancer. Respir Med. 109:803–812.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen D, Guo W, Qiu Z, Wang Q, Li Y, Liang
L, Liu L, Huang S, Zhao Y and He X: MicroRNA-30d 5p inhibits tumour
cell proliferation and motility by directly targeting CCNE2 in
non-small cell lung cancer. Cancer Lett. 362:208–217. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Yang WQ, Zhu H, Qian YY, Zhou L,
Ren YJ, Ren XC, Zhang L, Liu XP, Liu CG, et al: Regulation of
autophagy by miR-30d impacts sensitivity of anaplastic thyroid
carcinoma to cisplatin. Biochem Pharmacol. 87:562–570. 2014.
View Article : Google Scholar :
|
|
13
|
Xuan H, Xue W, Pan J, Sha J, Dong B and
Huang Y: Downregulation of miR-221, -30d, and -15a contributes to
pathogenesis of prostate cancer by targeting Bmi-1. Biochemistry
(Mosc). 80:276–283. 2015. View Article : Google Scholar
|
|
14
|
Ye Z, Zhao L, Li J, Chen W and Li X:
miR-30d blocked transforming growth factor β1-induced
epithelial-mesenchymal transition by targeting snail in ovarian
cancer cells. Int J Gynecol Cancer. 25:1574–1581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sablin EP, Blind RD, Uthayaruban R, Chiu
HJ, Deacon AM, Das D, Ingraham HA and Fletterick RJ: Structure of
Liver Receptor Homolog-1 (NR5A2) with IP3 hormone bound in the
ligand binding pocket. J Struct Biol. 192:342–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fayard E, Auwerx J and Schoonjans K:
LRH-1: An orphan nuclear receptor involved in development,
metabolism and steroidogenesis. Trends Cell Biol. 14:250–260. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stein S and Schoonjans K: Molecular basis
for the regulation of the nuclear receptor LRH-1. Curr Opin Cell
Biol. 33:26–34. 2015. View Article : Google Scholar
|
|
18
|
Schoonjans K, Dubuquoy L, Mebis J, Fayard
E, Wendling O, Haby C, Geboes K and Auwerx J: Liver receptor
homolog 1 contributes to intestinal tumor formation through effects
on cell cycle and inflammation. Proc Natl Acad Sci USA.
102:2058–2062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Benod C, Vinogradova MV, Jouravel N, Kim
GE, Fletterick RJ and Sablin EP: Nuclear receptor liver receptor
homologue-1 (LRH-1) regulates pancreatic cancer cell growth and
proliferation. Proc Natl Acad Sci USA. 108:16927–16931. 2011.
View Article : Google Scholar
|
|
20
|
Bayrer JR, Mukkamala S, Sablin EP, Webb P
and Fletterick RJ: Silencing LRH-1 in colon cancer cell lines
impairs proliferation and alters gene expression programs. Proc
Natl Acad Sci USA. 112:2467–2472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang SL, Zheng DZ, Lan FH, Deng XJ, Zeng
J, Li CJ, Wang R and Zhu ZY: Increased expression of hLRH-1 in
human gastric cancer and its implication in tumorigenesis. Mol Cell
Biochem. 308:93–100. 2008. View Article : Google Scholar
|
|
22
|
Ray RS, Rana B, Swami B, Venu V and
Chatterjee M: Vanadium mediated apoptosis and cell cycle arrest in
MCF7 cell line. Chem Biol Interact. 163:239–247. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Botrugno OA, Fayard E, Annicotte JS, Haby
C, Brennan T, Wendling O, Tanaka T, Kodama T, Thomas W, Auwerx J
and Schoonjans K: Synergy between LRH-1 and beta-catenin induces G1
cyclin-mediated cell proliferation. Mol Cell. 15:499–509. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gupta S, Sussman DA, Doubeni CA, Anderson
DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J and
Somsouk M: Challenges and possible solutions to colorectal cancer
screening for the underserved. J Natl Cancer Inst. 106:dju0322014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weng W, Feng J, Qin H, Ma Y and Goel A: An
update on miRNAs as biological and clinical determinants in
colorectal cancer: A bench-to-bedside approach. Future Oncol.
11:1791–1808. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ress AL, Perakis S and Pichler M:
microRNAs and colorectal cancer. Adv Exp Med Biol. 889:89–103.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamada A, Horimatsu T, Okugawa Y, Nishida
N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, et al: Serum
miR-21, miR-29a, and miR-125b are promising biomarkers for the
early detection of colorectal neoplasia. Clin Cancer Res.
21:4234–4242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yamada A, Cox MA, Gaffney KA, Moreland A,
Boland CR and Goel A: Technical factors involved in the measurement
of circulating microRNA biomarkers for the detection of colorectal
neoplasia. PLoS One. 9:e1124812014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao J, Liang L, Huang S, Ding J, Tan N,
Zhao Y, Yan M, Ge C, Zhang Z, Chen T, et al: MicroRNA-30d promotes
tumor invasion and metastasis by targeting Galphai2 in
hepatocellular carcinoma. Hepatology. 51:846–856. 2010.PubMed/NCBI
|
|
30
|
Kobayashi N, Uemura H, Nagahama K, Okudela
K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, et al:
Identification of miR-30d as a novel prognostic maker of prostate
cancer. Oncotarget. 3:1455–1471. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu C, Jin B, Chen L, Zhuo D, Zhang Z, Gong
K and Mao Z: MiR-30d induces apoptosis and is regulated by the
Akt/FOXO pathway in renal cell carcinoma. Cell Signal.
25:1212–1221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang W, Tian Y, Jiang S, Liu S, Zhao X
and Tian D: MicroRNA-376c suppresses non-small-cell lung cancer
cell growth and invasion by targeting LRH-1-mediated Wnt signaling
pathway. Biochem Biophys Res Commun. 473:980–986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang Y, Zhao Q, Fan L, Zhang Z, Tan B,
Liu Y and Li Y: Down-regulation of microRNA-381 promotes cell
proliferation and invasion in colon cancer through upregulation of
LRH-1. Biomed Pharmacother. 75:137–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Q, Zhao S, Pang X and Chi B:
MicroRNA-381 suppresses cell growth and invasion by targeting the
liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep.
35:1831–1840. 2016.
|
|
35
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar
|
|
36
|
Luu HH, Zhang R, Haydon RC, Rayburn E,
Kang Q, Si W, Park JK, Wang H, Peng Y, Jiang W and He TC:
Wnt/beta-catenin signaling pathway as a novel cancer drug target.
Curr Cancer Drug Targets. 4:653–671. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dong Y, Cao B, Zhang M, Han W, Herman JG,
Fuks F, Zhao Y and Guo M: Epigenetic silencing of NKD2, a major
component of Wnt signaling, promotes breast cancer growth.
Oncotarget. 6:22126–22138. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ozaki S, Ikeda S, Ishizaki Y, Kurihara T,
Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M and Asahara T:
Alterations and correlations of the components in the Wnt signaling
pathway and its target genes in breast cancer. Oncol Rep.
14:1437–1443. 2005.PubMed/NCBI
|
|
39
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
